← Browse by Condition
Medical Condition
focal segmental glomerulosclerosis
Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 1, Phase 2
NCT06664814 Phase 2
Recruiting
An Open-Label Phase 2 Study of N-Acetyl-D-Mannosamine (ManNAc) in Subjects With Primary Focal Segmental Glomerulosclerosis
Enrollment
30 pts
Location
United States
Sponsor
National Human Genome Research...
NCT06090227 Phase 1, Phase 2
Recruiting
AMPK-activation by Metformin in FSGS: AMP-FSGS
Enrollment
30 pts
Location
United States
Sponsor
Yale University
NCT06500702 Phase 2
Recruiting
A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease
Enrollment
84 pts
Location
United States, Argen...
Sponsor
Sanofi
NCT06065852
Recruiting
National Registry of Rare Kidney Diseases
Enrollment
35,000 pts
Location
United Kingdom
Sponsor
UK Kidney Association